TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.

Bayesian network Causal inference LUAD Prognosis Prognostic factor TTF-1 Tumor grade

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
10 Dec 2023
Historique:
received: 30 10 2023
revised: 03 12 2023
accepted: 04 12 2023
medline: 16 12 2023
pubmed: 16 12 2023
entrez: 15 12 2023
Statut: aheadofprint

Résumé

Thyroid transcription factor 1 (TTF-1) is a well-established independent prognostic factor in lung adenocarcinoma (LUAD), irrespective of stage. This study aims to determine if TTF-1's prognostic impact is solely based on histomorphological differentiation (tumor grading) or if it independently relates to a biologically more aggressive phenotype. We analyzed a large bi-centric LUAD cohort to accurately assess TTF-1's prognostic value in relation to tumor grade. We studied 447 patients with resected LUAD from major German lung cancer centers (Berlin and Cologne), correlating TTF-1 status and grading with clinical, pathologic, and molecular data, alongside patient outcomes. TTF-1's impact was evaluated through univariate and multivariate Cox regression. Causal graph analysis was used to identify and account for potential confounders, improving the statistical estimation of TTF-1's predictive power for clinical outcomes. Univariate analysis revealed TTF-1 positivity associated with significantly longer disease-free survival (DFS) (median log HR -0.83; p = 0.018). Higher tumor grade showed a non-significant association with shorter DFS (median log HR 0.30; p = 0,62 for G1 to G2 and 0.68; p = 0,34 for G2 to G3). In multivariate analysis, TTF-1 positivity resulted in a significantly longer DFS (median log HR -0.65; p = 0.05) independent of all other parameters, including grading. Adjusting for potential confounders as indicated by the causal graph confirmed the superiority of TTF-1 over tumor grading in prognostics power. TTF-1 status predicts relapse and survival in LUAD independently of tumor grading. The prognostic power of tumor grading is limited to TTF-1-positive patients, and the effect size of TTF-1 surpasses that of tumor grading. We recommend including TTF1 status as a prognostic factor in the diagnostic guidelines of LUAD.

Identifiants

pubmed: 38100920
pii: S0959-8049(23)00776-1
doi: 10.1016/j.ejca.2023.113474
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113474

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Simon Schallenberg (S)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany. Electronic address: simon.schallenberg@charite.de.

Gabriel Dernbach (G)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany; Aignostics GmbH, 10555 Berlin, Germany; BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, Germany. Electronic address: gabriel.dernbach@charite.de.

Mihnea P Dragomir (MP)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Berlin Institute of Health (BIH), Berlin, Germany.

Georg Schlachtenberger (G)

Department of Cardiothoracic Surgery, University Hospital Cologne, Germany.

Kyrill Boschung (K)

Bethanien Hospital, Clinic of Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care, Institute of Pneumology at the University of Cologne, Solingen, Germany.

Corinna Friedrich (C)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Proteomics Platform, Berlin, Germany.

Kai Standvoss (K)

Aignostics GmbH, 10555 Berlin, Germany.

Lukas Ruff (L)

Aignostics GmbH, 10555 Berlin, Germany.

Philipp Anders (P)

Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary.

Christian Grohé (C)

Klinik für Pneumologie, Evangelische Lungenklinik Berlin Buch, Berlin, Germany.

Winfried Randerath (W)

Bethanien Hospital, Clinic of Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care, Institute of Pneumology at the University of Cologne, Solingen, Germany.

Sabine Merkelbach-Bruse (S)

Institute of Pathology, University Hospital Cologne, Germany.

Alexander Quaas (A)

Institute of Pathology, University Hospital Cologne, Germany.

Matthias Heldwein (M)

Department of Cardiothoracic Surgery, University Hospital Cologne, Germany.

Ulrich Keilholz (U)

Charite Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.

Jens Khosro Hekmat (JK)

Department of Cardiothoracic Surgery, University Hospital Cologne, Germany.

Carsten Rückert (C)

Department of General, Visceral, Vascular and Thoracic Surgery, Charité-Universitätsmedizin Berlin, Germany.

Reinhard Büttner (R)

Institute of Pathology, University Hospital Cologne, Germany.

David Horst (D)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.

Frederick Klauschen (F)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany; BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology, Ludwig-Maximilians-University Munich, Thalkirchner Str. 36, 80337 München, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Munich Partner Site, Heidelberg, Germany.

Nikolaj Frost (N)

Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.

Classifications MeSH